NASDAQ:APGE Apogee Therapeutics Q4 2024 Earnings Report $38.37 +1.23 (+3.31%) Closing price 04:00 PM EasternExtended Trading$38.69 +0.32 (+0.83%) As of 04:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Apogee Therapeutics EPS ResultsActual EPS-$1.19Consensus EPS -$0.94Beat/MissMissed by -$0.25One Year Ago EPSN/AApogee Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AApogee Therapeutics Announcement DetailsQuarterQ4 2024Date3/3/2025TimeBefore Market OpensConference Call DateMonday, March 3, 2025Conference Call Time7:00AM ETUpcoming EarningsApogee Therapeutics' Q2 2025 earnings is scheduled for Monday, August 11, 2025, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q2 2025 Earnings ReportConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Apogee Therapeutics Earnings HeadlinesBTIG Raises PT on Apogee Therapeutics (APGE) to $115 From $100, Keeps a Buy Rating2 hours ago | finance.yahoo.comCanaccord Genuity Reiterated a Buy Rating on Apogee Therapeutics (APGE)July 14 at 12:47 PM | msn.comA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.July 16 at 2:00 AM | American Alternative (Ad)Stifel reiterates Buy rating on Apogee Therapeutics stock amid positive ...July 11, 2025 | investing.comApogee Therapeutics Shares Surge After Promising Eczema Drug Trial ResultsJuly 9, 2025 | msn.comWedbush Reiterates "Outperform" Rating for Apogee Therapeutics (NASDAQ:APGE)July 9, 2025 | americanbankingnews.comSee More Apogee Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Apogee Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Apogee Therapeutics and other key companies, straight to your email. Email Address About Apogee TherapeuticsApogee Therapeutics (NASDAQ:APGE), Inc. (NASDAQ: APGE) is a clinical-stage biopharmaceutical company dedicated to the development of small-molecule therapies that modulate proteostasis pathways. The company’s research efforts are focused on identifying and advancing novel compounds capable of restoring or enhancing protein homeostasis in cells, with potential applications in oncology, autoimmune disorders and other diseases driven by dysregulated protein processing. Apogee leverages a proprietary drug discovery platform that combines structure-based design, high-throughput screening and phenotypic assays to optimize lead candidates. Its pipeline includes multiple preclinical and early clinical-stage assets, each targeting distinct molecular mechanisms involved in cell signaling, protein folding and degradation pathways. The company collaborates with academic institutions and research organizations to accelerate the translation of laboratory findings into therapeutic opportunities. Based in the United States, Apogee Therapeutics maintains a focused R&D infrastructure designed to support rapid proof-of-concept studies and strategic partnerships. Its management team comprises seasoned professionals with expertise in drug development, regulatory affairs and commercialization, positioning the company to achieve clinical milestones and pursue collaboration or licensing arrangements that can further advance its pipeline.Written by Jeffrey Neal JohnsonView Apogee Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles 3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom3 Catalysts Converge on Intel Ahead of a Critical Earnings ReportSmith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still Strong Upcoming Earnings Cintas (7/17/2025)Interactive Brokers Group (7/17/2025)Netflix (7/17/2025)PepsiCo (7/17/2025)Abbott Laboratories (7/17/2025)Elevance Health (7/17/2025)GE Aerospace (7/17/2025)American Noble Gas (7/17/2025)Marsh & McLennan Companies (7/17/2025)Novartis (7/17/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
